These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32634310)

  • 1. Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria.
    Skepper CK; Armstrong D; Balibar CJ; Bauer D; Bellamacina C; Benton BM; Bussiere D; De Pascale G; De Vicente J; Dean CR; Dhumale B; Fisher LM; Fuller J; Fulsunder M; Holder LM; Hu C; Kantariya B; Lapointe G; Leeds JA; Li X; Lu P; Lvov A; Ma S; Madhavan S; Malekar S; McKenney D; Mergo W; Metzger L; Moser HE; Mutnick D; Noeske J; Osborne C; Patel A; Patel D; Patel T; Prajapati K; Prosen KR; Reck F; Richie DL; Rico A; Sanderson MR; Satasia S; Sawyer WS; Selvarajah J; Shah N; Shanghavi K; Shu W; Thompson KV; Traebert M; Vala A; Vala L; Veselkov DA; Vo J; Wang M; Widya M; Williams SL; Xu Y; Yue Q; Zang R; Zhou B; Rivkin A
    J Med Chem; 2020 Jul; 63(14):7773-7816. PubMed ID: 32634310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
    Lapointe G; Skepper CK; Holder LM; Armstrong D; Bellamacina C; Blais J; Bussiere D; Bian J; Cepura C; Chan H; Dean CR; De Pascale G; Dhumale B; Fisher LM; Fulsunder M; Kantariya B; Kim J; King S; Kossy L; Kulkarni U; Lakshman J; Leeds JA; Ling X; Lvov A; Ma S; Malekar S; McKenney D; Mergo W; Metzger L; Mhaske K; Moser HE; Mostafavi M; Namballa S; Noeske J; Osborne C; Patel A; Patel D; Patel T; Piechon P; Polyakov V; Prajapati K; Prosen KR; Reck F; Richie DL; Sanderson MR; Satasia S; Savani B; Selvarajah J; Sethuraman V; Shu W; Tashiro K; Thompson KV; Vaarla K; Vala L; Veselkov DA; Vo J; Vora B; Wagner T; Wedel L; Williams SL; Yendluri S; Yue Q; Yifru A; Zhang Y; Rivkin A
    J Med Chem; 2021 May; 64(9):6329-6357. PubMed ID: 33929852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.
    Tari LW; Li X; Trzoss M; Bensen DC; Chen Z; Lam T; Zhang J; Lee SJ; Hough G; Phillipson D; Akers-Rodriguez S; Cunningham ML; Kwan BP; Nelson KJ; Castellano A; Locke JB; Brown-Driver V; Murphy TM; Ong VS; Pillar CM; Shinabarger DL; Nix J; Lightstone FC; Wong SE; Nguyen TB; Shaw KJ; Finn J
    PLoS One; 2013; 8(12):e84409. PubMed ID: 24386374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperazine-azole-fluoroquinolone hybrids: Conventional and microwave irradiated synthesis, biological activity screening and molecular docking studies.
    Mermer A; Faiz O; Demirbas A; Demirbas N; Alagumuthu M; Arumugam S
    Bioorg Chem; 2019 Apr; 85():308-318. PubMed ID: 30654222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.
    Mustaev A; Malik M; Zhao X; Kurepina N; Luan G; Oppegard LM; Hiasa H; Marks KR; Kerns RJ; Berger JM; Drlica K
    J Biol Chem; 2014 May; 289(18):12300-12. PubMed ID: 24497635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of Type II Topoisomerase Mutations to Fluoroquinolone Resistance in Enterococcus faecium from Japanese Clinical Setting.
    Urushibara N; Suzaki K; Kawaguchiya M; Aung MS; Shinagawa M; Takahashi S; Kobayashi N
    Microb Drug Resist; 2018; 24(1):1-7. PubMed ID: 28504916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
    Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
    J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.
    Charrier C; Salisbury AM; Savage VJ; Moyo E; Forward H; Ooi N; Cheung J; Metzger R; McGarry D; Walker R; Cooper IR; Ratcliffe AJ; Stokes NR
    J Antimicrob Chemother; 2016 Oct; 71(10):2831-9. PubMed ID: 27353465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.
    Kocsis B; Domokos J; Szabo D
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):34. PubMed ID: 27215369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitafloxacin: antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV.
    Deguchi T; Kikuchi M; Yasuda M; Ito S
    J Infect Chemother; 2015 Jan; 21(1):74-5. PubMed ID: 25245990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
    Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of isoquinoline sulfonamides as allosteric gyrase inhibitors with activity against fluoroquinolone-resistant bacteria.
    Bakker AT; Kotsogianni I; Avalos M; Punt JM; Liu B; Piermarini D; Gagestein B; Slingerland CJ; Zhang L; Willemse JJ; Ghimire LB; van den Berg RJHBN; Janssen APA; Ottenhoff THM; van Boeckel CAA; van Wezel GP; Ghilarov D; Martin NI; van der Stelt M
    Nat Chem; 2024 Sep; 16(9):1462-1472. PubMed ID: 38898213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of aminopiperidine based potent & novel topoisomerase inhibitor with broad spectrum anti-bacterial activity.
    Desai J; Patel B; Panchal N; Gite A; Darji B; Viswanathan K; Trivedi J; Vyas P; Pawar V; Giri P; S S; Sharma R; Jain M; Iyer P; Kumar S
    Bioorg Med Chem Lett; 2024 Oct; 111():129911. PubMed ID: 39067715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.
    Dougherty TJ; Nayar A; Newman JV; Hopkins S; Stone GG; Johnstone M; Shapiro AB; Cronin M; Reck F; Ehmann DE
    Antimicrob Agents Chemother; 2014 May; 58(5):2657-64. PubMed ID: 24566174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2).
    Singh SB; Kaelin DE; Wu J; Miesel L; Tan CM; Black T; Nargund R; Meinke PT; Olsen DB; Lagrutta A; Lu J; Patel S; Rickert KW; Smith RF; Soisson S; Sherer E; Joyce LA; Wei C; Peng X; Wang X; Fukuda H; Kishii R; Takei M; Takano H; Shibasaki M; Yajima M; Nishimura A; Shibata T; Fukuda Y
    Bioorg Med Chem Lett; 2015 May; 25(9):1831-5. PubMed ID: 25851938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents.
    Khan T; Sankhe K; Suvarna V; Sherje A; Patel K; Dravyakar B
    Biomed Pharmacother; 2018 Jul; 103():923-938. PubMed ID: 29710509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
    Mitton-Fry MJ; Brickner SJ; Hamel JC; Barham R; Brennan L; Casavant JM; Ding X; Finegan S; Hardink J; Hoang T; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Subramanyam C; Plotkin M; Reilly U; Schafer J; Stone GG; Uccello DP; Wisialowski T; Yoon K; Zaniewski R; Zook C
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3353-3358. PubMed ID: 28610977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
    Trzoss M; Bensen DC; Li X; Chen Z; Lam T; Zhang J; Creighton CJ; Cunningham ML; Kwan B; Stidham M; Nelson K; Brown-Driver V; Castellano A; Shaw KJ; Lightstone FC; Wong SE; Nguyen TB; Finn J; Tari LW
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1537-43. PubMed ID: 23294697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Korzheva N; Davies TA; Goldschmidt R
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria.
    Charrier C; Salisbury AM; Savage VJ; Duffy T; Moyo E; Chaffer-Malam N; Ooi N; Newman R; Cheung J; Metzger R; McGarry D; Pichowicz M; Sigerson R; Cooper IR; Nelson G; Butler HS; Craighead M; Ratcliffe AJ; Best SA; Stokes NR
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.